Clinical Trials
-
Principal Investigator:
Philip L. De Jager, MD, PHDThe purpose of this study is to determine whether different genes are related to the amount of immune cell activity that occurs in the brain in patients with Alzheimer's disease. Participation in this study involves memory testing, a blood draw, MRI, and two PET scans. The second PET scan will involve putting a catheter in your wrist to draw blood during the scan. You will be compensated $500. After one year, we will invite you back to repeat some tests. -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Chih-Chun Lin, MD, PhDFoxBioNet ECV-004 is an observational study sponsored by the Michael J. Fox Foundation for Parkinson's Research. The purpose of this study is to investigate a gene called LRRK2. Mutations in the LRRK2 gene are associated with Parkinson's disease (PD), and mutation carriers have greater LRRK2 protein activity. The goal of this study is to identify reliable markers of LRRK2 activity in human cerebrospinal fluid. This study is enrolling volunteers aged 30 and older, with and without Parkinson's disease, with and without LRRK2 mutations, to undergo a lumbar puncture to collect cerebrospinal fluid... -
Principal Investigator:
Chih-Chun Lin, MD, PhDFoxBioNet ECV-004 is an observational study sponsored by the Michael J. Fox Foundation for Parkinson's Research. The purpose of this study is to investigate a gene called LRRK2. Mutations in the LRRK2 gene are associated with Parkinson's disease (PD), and mutation carriers have greater LRRK2 protein activity. The goal of this study is to identify reliable markers of LRRK2 activity in human cerebrospinal fluid. This study is enrolling volunteers aged 30 and older, with and without Parkinson's disease, with and without LRRK2 mutations, to undergo a lumbar puncture to collect cerebrospinal fluid... -
Principal Investigator:
Karen S. Marder, MD, MPHThe Parkinson's Progression Markers Initiative (PPMI) seeks to uncover insights into Parkinson's disease (PD) onset and progression that could transform how we diagnose, treat, and potentially prevent PD. PPMI has already contributed to a new understanding around disease biology and experience, and its findings and design have led to more efficient clinical research. Now PPMI is looking to bring together a larger and more diverse group of individuals both with and without PD who can help contribute to a more detailed look into the way the disease develops and changes over time. The study will... -
Principal Investigator:
Sarah A. O'Shea, MDThe DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying on task, impaired judgment, and difficulty multi-tasking. There will be an open-label extension (OLE) study, which is planned to begin later in 2022. Participants who are interested can speak to the study team. To be eligible for the study, you... -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of the study is to test the following: 1) The safety and tolerability (how you feel when you take the drug) of the study drug, 2) The pharmacokinetics (PK) (how the study drug is absorbed within your body, spread throughout your body, and eliminated from your body) of the study drug, 3) The pharmacodynamics (PD) (how the study drug affects certain proteins related to your cancer) of the study drug 4) The initial clinical effect (how the study drug affects your cancer) of the study drug, and 5) To determine the most appropriate dose (strength) and how often the drug should be taken... -
Principal Investigator:
Karen L. Bell, MDWe are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks. -
Principal Investigator:
Karen L. Bell, MDWe are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks. -
Principal Investigator:
Thomas H. Brannagan III, MDThe main goal of this study is to look at the effect and safety of efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP). Another goal of the study is to collect information on how well efgartigimod works, how the body processes efgartigimod, what efgartigimod does to the body, and how your immune system reacts to efgartigimod. This trial will be conducted in 2 stages: An open-label Stage A and a randomized-withdrawal, double-blind, placebo-controlled Stage B. Approximately 360 patients aged 18 years and older male and non-pregnant female are planned to...